ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS DisordersBRISBANE, Calif., July 26, 2024-- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a $30 million Series A financing, bringing the total raised so far to $54M, including the seed financing in 2021.

ReviR Therapeutics筹集3000万美元的A系列融资，以推进其针对多种中枢神经系统疾病的专有口服遗传药物。加利福尼亚州布里斯班，2024年7月26日——ReviR Therapeutics是一家专注于开发用于神经遗传疾病的小分子RNA调节剂的人工智能生物技术公司，今天宣布，它已成功完成3000万美元的A系列融资，迄今为止筹集的资金总额达到5400万美元，包括2021年的种子融资。

The financing was led by Lapam Capital with strong support from existing investors CDH Investments, 5Y Capital, and Yael Capital, as well as new participants XtalPi and the Charcot-Marie Tooth Research Foundation (CMTRF)..

融资由拉帕姆资本牵头，现有投资者CDH Investments、5Y Capital和Yael Capital以及新参与者XtalPi和Charcot Marie Tooth Research Foundation（CMTRF）大力支持。。

These funds will be used to further augment ReviR's AI-driven drug discovery VoyageR platform, which will be leveraged to advance proprietary chemical matter for novel and undruggable targets and to support clinical development of treatments for Huntington's disease (HD), Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and other neurological disorders..

这些资金将用于进一步增强ReviR的人工智能驱动的药物发现旅行者平台，该平台将用于推进新型和不可药用靶标的专有化学物质，并支持亨廷顿舞蹈病（HD），Charcot-Marie-Tooth病（CMT），肌萎缩侧索硬化症（ALS）和其他神经系统疾病治疗的临床开发。。

Since its founding in 2021, ReviR Therapeutics has assembled an expert global drug discovery team and built a robust customized AI platform. ReviR's platform strategy focuses on developing non-invasive, orally administered genetic therapies that use small molecules to regulate RNA splicing and influence protein expression.

自2021年成立以来，ReviR Therapeutics已经组建了一个专家级的全球药物发现团队，并建立了一个强大的定制AI平台。ReviR的平台策略专注于开发非侵入性口服遗传疗法，该疗法使用小分子来调节RNA剪接并影响蛋白质表达。

This approach leverages the VoyageR platform to develop potent, safe, and selective RNA splicing modulators for a broad range of diseases. .

这种方法利用旅行者平台开发有效，安全和选择性的RNA剪接调节剂，用于多种疾病。

While over 80% of disease-related proteins are considered 'undruggable', ReviR's novel genetic therapies target RNA, upstream of protein synthesis to stop causal disease progression. Other genetic therapy modalities often encounter delivery challenges, particularly with crossing the blood-brain barrier, and can be invasive, especially for CNS diseases.

虽然超过80%的疾病相关蛋白被认为是“不可治疗的”，但ReviR的新型遗传疗法靶向蛋白质合成上游的RNA，以阻止因果疾病的进展。其他基因治疗方式通常会遇到分娩挑战，特别是跨越血脑屏障，并且可能是侵入性的，尤其是对于中枢神经系统疾病。

ReviR is currently focused on treating neurodegenerative diseases and rare genetic disorders while exploring partnerships in the fields of oncology, immunology & inflammation, and metabolic diseases. .

ReviR目前专注于治疗神经退行性疾病和罕见遗传疾病，同时探索肿瘤学，免疫学和炎症以及代谢疾病领域的合作伙伴关系。

Dr. Peng Yue, Co-founder and CEO of ReviR Therapeutics, stated, 'Neurological diseases affect a large number of individuals worldwide, many of which do not have disease modifying therapies available. ReviR is dedicated to developing accessible, safer genetic therapies that can be administered orally.

ReviR Therapeutics联合创始人兼首席执行官彭跃博士表示，“神经系统疾病影响着全球许多人，其中许多人没有可用的疾病缓解疗法。ReviR致力于开发可口服的、更安全的基因疗法。

We value the support from new and existing investors as we progress from initial platform development to clinical trials, continually enhancing our AI platform and advancing our pipeline. As we move forward, we will continue to raise funds as an extension to our Series A to support additional programs entering clinical trials.'.

随着我们从初始平台开发到临床试验的进展，我们重视新投资者和现有投资者的支持，不断增强我们的AI平台并推进我们的管道。随着我们的前进，我们将继续筹集资金，作为A系列的延伸，以支持进入临床试验的其他项目。”。

Mr. Zhihua Yu, Founding Partner of Lapam Capital, commented, 'Small molecule targeting RNA represents a highly challenging and innovative field. RNA targets offer greater potential compared to protein targets, but also present higher development difficulties. We have great confidence in ReviR's platform, which can identify potential RNA targets and efficiently develop safe and effective RNA-targeted therapies.

Lapam Capital的创始合伙人余志华先生评论道：“靶向RNA的小分子代表了一个极具挑战性和创新性的领域。与蛋白质靶标相比，RNA靶标具有更大的潜力，但也存在更高的开发困难。我们对ReviR的平台充满信心，该平台可以识别潜在的RNA靶标并有效开发安全有效的RNA靶向疗法。

This enables the development of orally administrable small molecule drugs for previously undruggable targets. ReviR has built a team with extensive experience in computational biology, RNA biology, and drug discovery, showcasing exceptional execution capabilities. We are confident the company will advance its pipeline to clinical trials soon, benefiting patients worldwide.

这使得能够为先前不可药用的靶标开发口服给药的小分子药物。ReviR建立了一个在计算生物学、RNA生物学和药物发现方面拥有丰富经验的团队，展示了非凡的执行能力。我们相信该公司将很快推进临床试验，使全球患者受益。

We will continue to support ReviR with our experience and resources as it grows.' .

随着ReviR的发展，我们将继续以我们的经验和资源支持它。”。

Dr. Shuhao Wen, Co-founder and Chairman of XtalPi, added, 'At XtalPi, we recognize the immense potential of small molecule targeting RNA to significantly expand the boundaries of drug discovery. Our collaboration with ReviR, leveraging XtalPi's cutting-edge AI and robotics drug discovery solutions with ReviR's specialized capabilities in RNA structural analysis, small molecule screening, and target engagement evaluation, has already yielded promising pipeline results.

XtalPi联合创始人兼董事长舒浩文博士补充说，“在XtalPi，我们认识到小分子靶向RNA在显着扩大药物发现边界方面的巨大潜力。我们与ReviR的合作，利用XtalPi的尖端AI和机器人药物发现解决方案以及ReviR在RNA结构分析，小分子筛选和靶标参与评估方面的专业能力，已经产生了有希望的管道结果。

Our collective expertise is aimed at propelling these innovations into clinical research, tapping into the vast and underexplored potential of RNA targets, and delivering effective novel therapeutic options to patients worldwide.'.

我们的集体专业知识旨在推动这些创新进入临床研究，挖掘RNA靶标的巨大和未充分开发的潜力，并为全球患者提供有效的新型治疗选择。”。

About ReviR Therapeutics

关于ReviR Therapeutics

ReviR Therapeutics is an emerging biopharmaceutical company focused on the development of RNA-targeting small molecule therapies that modulate the causal genes of diseases, including CNS diseases, cancer, and other rare genetically-defined diseases. The company is utilizing cutting-edge technologies to develop therapies with the goal of developing disease modifying therapies that are highly specific, efficacious, and safe.

ReviR Therapeutics是一家新兴的生物制药公司，专注于开发靶向RNA的小分子疗法，以调节疾病的致病基因，包括中枢神经系统疾病，癌症和其他罕见的遗传定义疾病。该公司正在利用尖端技术开发治疗方法，目的是开发高度特异性，有效性和安全性的疾病缓解疗法。

The company's initial focus is to apply SpliceR modulation technologies towards RNA targets of genetic diseases with limited or no treatment options. ReviR Therapeutics was founded in 2021 by leaders in computational biology, AI/ML, RNA biology, and drug discovery. The company is headquartered in Brisbane, CA.

该公司最初的重点是将剪接调节技术应用于遗传疾病的RNA靶标，而治疗选择有限或没有。ReviR Therapeutics由计算生物学，AI/ML，RNA生物学和药物发现领域的领导者于2021年成立。该公司总部位于加利福尼亚州布里斯班。

For more information, visit our website www.revirtx.com or email info@revirtx.com..

For more information, visit our website www.revirtx.com or email info@revirtx.com..

About Lapam Capital

关于Lapam Capital

Lapam Capital is a leading healthcare venture capital firm managing six funds with more than 1.5 billion dollars under management. Lapam Capital focuses on investments in early to mid- stage fast-growing companies that have innovative pharmaceuticals and medical devices. Its investment portfolio currently consists of 120+ projects, of which innovative drug therapeutics projects account for over 80%, including Betta Pharma, RemeGen Co.

Lapam Capital是一家领先的医疗保健风险投资公司，管理着六只基金，管理资金超过15亿美元。Lapam Capital专注于投资于拥有创新药品和医疗设备的早期至中期快速增长的公司。其投资组合目前由120多个项目组成，其中创新药物治疗项目占80%以上，包括Betta Pharma，RemeGen Co。

Ltd., Gyre Therapeutics, Asieris Pharmaceuticals, ImmuneOnco Biopharmaceuticals, Binhui Biotech, Biostar Pharmaceuticals, Eyebright Medical Technology Ltd., and many other companies with great potential. Lapam Capital has a professional investment team with more than 20 years of international and domestic biopharmaceutical industry R&D and management experience and can provide comprehensive value-added support for the invested companies..

有限公司、Gyre Therapeutics、Asieris Pharmaceuticals、ImmuneOnco Biopharmaceuticals、Binhui Biotech、Biostar Pharmaceuticals、Eyebright Medical Technology Ltd.和许多其他具有巨大潜力的公司。Lapam Capital拥有一支拥有20多年国际国内生物制药行业研发和管理经验的专业投资团队，可为被投资公司提供全面的增值支持。。

About XtalPi Inc.

关于XtalPi股份有限公司。

XtalPi Inc. ('QuantumPharm', stock code: 2228.HK) is a quantum physics-based, AI-powered, and robotics-driven, innovative R&D platform company. Established in 2015 by three postdoctoral physicists at Massachusetts Institute of Technology (MIT), the Company is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors.

XtalPi Inc.（“QuantumPharm”，股票代码：2228。HK）是一家基于量子物理，人工智能驱动，机器人驱动的创新研发平台公司。该公司由麻省理工学院（MIT）的三位博士后物理学家于2015年成立，致力于推动生命科学和材料科学领域的智能化和数字化转型。

The Company combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions and services for biomedicine, chemical, renewable energy and advanced materials industries globally..

该公司结合量子物理、人工智能、云计算和大规模机器人技术，为全球生物医学、化学、可再生能源和先进材料行业提供研发解决方案和服务。。

About Charcot-Marie Tooth Research Foundation

关于Charcot-Marie-Tooth研究基金会

CMT Research Foundation (CMTRF) is a patient-led, non-profit focused on delivering treatments and cures for CMT. The foundation identifies significant obstacles or deficiencies impeding progress toward a cure and seeks out collaborators to address these issues. To date, CMTRF has funded 24 projects, of which 8 are completed.

。该基金会确定了阻碍治愈进展的重大障碍或缺陷，并寻找合作者来解决这些问题。迄今为止，CMTRF已资助24个项目，其中8个已完成。

Of those 8 completed projects, 5 have clinical candidates. CMTRF's mission to invest in promising science with high potential of leading to treatments and cures was proven effective and ground-breaking when DTx Pharma with a CMTRF- backed program as its lead candidate was acquired by Novartis for $1 billion.

在这8个已完成的项目中，有5个具有临床候选人。诺华斥资10亿美元收购了拥有CMTRF支持计划的DTx Pharma作为其主要候选人，这证明了CMTRF的使命是投资于有前景的科学，并具有很高的治疗和治愈潜力。

Founded by two patients who are driven to expedite drug delivery to people who live with CMT, the 501(c)(3) federal tax-exempt organization is supported by personal and corporate financial gifts..

501（c）（3）联邦免税组织由两名患者创建，他们致力于加快向CMT患者的药物输送，该组织得到个人和公司财务礼物的支持。。